GuidelineEuropean journal of nuclear medicine and molecular imaging2012
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.
Guideline in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed.
- Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors.PloS one · 2016Trial
- Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.Clinical nuclear medicine · 2014Trial
- Future scenarios of radioligand therapy in pheochromocytomas and paragangliomas.EJNMMI reports · 2026Review
- FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications.Endocrine-related cancer · 2026Review
- Synchronous Bilateral Shamblin Type III Carotid Body Tumors and Adrenal Pheochromocytoma with SDHD Mutation: A Rare Presentation, with Multimodality Imaging Findings.World journal of nuclear medicine · 2026Article
- Article
- Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.Insights into imaging · 2026Article
- Hypertensive retinopathy as the first manifestation of extra-adrenal paraganglioma.Hormones (Athens, Greece) · 2025Article
- Illuminating the Hidden: Standardizing Cardiac MIBG Imaging for Sympathetic Dysfunction.Journal of nuclear medicine technology · 2025Review
- [Germline mutations define the prognosis and therapy of pheochromocytomas and paragangliomas].Magyar onkologia · 2025Review
- Pheochromocytomas and Paragangliomas-Current Management.Cancers · 2025Review
- Article
- Article
- Incidental detection of purely cystic pheochromocytoma in a young adult presenting with lower urinary tract infection.Radiology case reports · 2024Article
- Article
- Endocrinology application of molecular imaging: current role of PET/CT.Journal of endocrinological investigation · 2024Review
- Small Incidental Pheochromocytoma Presenting With Normal or Borderline High 24-hour Urine Fractionated Metanephrines.JCEM case reports · 2024Article
- Non‑functional paraganglioma: A case report.Experimental and therapeutic medicine · 2024Article
- Deceptive Brown Adipose Tissue.Journal of the ASEAN Federation of Endocrine Societies · 2024Article
- Tumor metabolism in pheochromocytomas: clinical and therapeutic implications.Exploration of targeted anti-tumor therapy · 2024Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeRadionuclide imaging of phaeochromocytomas (PCCs) and paragangliomas (PGLs) involves various functional imaging techniques and approaches for accurate diagnosis, staging and tumour characterization. The purpose of the present guidelines is to assist nuclear medicine practitioners in performing, interpreting and reporting the results of the currently available SPECT and PET imaging approaches. These guidelines are intended to present information specifically adapted to European practice.
methodsGuidelines from related fields, issued by the European Association of Nuclear Medicine and the Society of Nuclear Medicine, were taken into consideration and are partially integrated within this text. The same was applied to the relevant literature, and the final result was discussed with leading experts involved in the management of patients with PCC/PGL. The information provided should be viewed in the context of local conditions, laws and regulations.
conclusionAlthough several radionuclide imaging modalities are considered herein, considerable focus is given to PET imaging which offers high sensitivity targeted molecular imaging approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.